Health

STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:25 UTC.

Briefings

Argenx announced Thursday that its Vyvgart drug failed to outperform placebo in a Phase 3 trial for Sjögren’s disease, a chronic autoimmune disorder. This marks a significant setback for Argenx, which previously led to a 13% drop in stock value on Thursday morning. The study involved patients with Sjögren’s disease, and Argenx has historically achieved success in similar autoimmune disorder trials before this failure.

Key points

• Vyvgart failed to outperform placebo in a Phase 3 trial for Sjögren’s disease, resulting in a 13% drop in Argenx's stock value on Thursday morning.
• Argenx previously achieved success in similar autoimmune disorder trials before this failure, indicating a potential shift in its trajectory.

Context

Argenx is a biotech company that has historically led to success in autoimmune disorder trials, including a 13% drop in stock value on Thursday morning following the Vyvgart failure. The company has previously achieved success in similar autoimmune disorder trials before this failure.

Limitations

The evidence is limited to a single Phase 3 trial result for Vyvgart in Sjögren’s disease. No additional background on Argenx's history or future plans is supplied. The study involved patients with Sjögren’s disease, and Argenx has historically achieved success in similar autoimmune disorder trials before this failure.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 13/11/2026, 09:00:04 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihbo243ccy2fmisa6dkfjifuuor2xitwey3jnmhtoxmmgly5ozquu